A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial
Abstract Background Combined serplulimab and chemotherapy demonstrated improved clinical survival outcomes in patients with advanced esophageal squamous cell carcinoma (ESCC) and PD-L1 combined positive scores (CPS) ≥ 1. The present study aimed to evaluate the economic viability of integrating serpl...
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
BMC
2024-01-01
|
| coleção: | Cost Effectiveness and Resource Allocation |
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.1186/s12962-024-00516-5 |